+ 0.15
+ 0.08%

Quarterly Earnings: Experion, InMed Pharmaceuticals, Smoke Cartel

September 8, 2020 2:41 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print More

Here's a summary of the latest earnings and operational updates in the cannabis industry.

InMed Pharmaceuticals Posts Record Net Loss Of $11.9M

InMed Pharmaceuticals Inc. (TSX:IN) (OTCQX: IMLFFreported its earnings for the fiscal year 2020.

The Vancouver-based company posted a record net loss of $11.9 million, versus a net loss of $13.3 million for the last year.

In addition, its research and development expenses were $7.1 million, up by around 27% compared to the previous year.

Its general and administrative expenses decreased by approximately 8% over the year to $3.5 million.

The company's cash equivalents and short-term investments amounted to $8 million, compared to $18 million in 2019.

InMed also noted it applied to join other cannabis-related companies listed on the Nasdaq Stock Market.

Smoke Cartel Revenue Spikes 478.6% Sequentially

Smoke Cartel, Inc. (OTC:SMKCrevealed its revenue increased by 478.6% sequentially, and 258.6% over year-date, to $2.3 million and $3.4 million, respectively.

The Savannah, Georgia-based online retailer noted its net income amounted to $576,200 in the second quarter of this fiscal year. Its year-to-date net income was $636,500 versus a loss of $1,013 million in the last year.

In addition, cash and cash equivalents were $909,000 as of June 30, the press release said.

The company said it saw a "massive upsurge in demand for our products" as of March, due to the current health crisis.

Experion Increases Operational Capacities, Sells Over 92,000 Pre-Rolls

Experion Holdings Ltd. (TSXV:EXP) (OTCQB: EXPFF) announced some strategic updates and operational milestones for the last nine months of this fiscal year.

Over the last nine months, the Vancouver-based company boosted its licensed space by increasing its cannabis flower cultivation capacities by 20% and processing space by 100%.

To date, Experion sold over 92,000 pre-rolls, the press release said.

In addition, it obtained Health Canada's approval to include edibles, topicals, and concentrates.

The company also developed a strain-specific concentrate line and a vegan gummy edible product poised to go to market in the following two months.


Cannabis Earnings News

Related Articles

LeafLogix CEO: Compliance Software Is Crucial For Cannabis Post-Legalization

No matter which U.S. Presidential candidate — incumbent Donald Trump or former Vice President Joe Biden — wins on Nov. 3, federal legalization of cannabis is something neither major party ticket supports.  read more

Cable Provider 4Cable To Venture Into CBD Space, Considers Two Acquisitions

4Cable TV International Inc. (PINK: CATV) is looking to acquire two CBD companies. The Port St. Lucie, Florida-based company expects to announce its final decision in the weeks to come. read more

Harborside Poised To Take Over Another California Dispensary, Acquires 50.1% Stake In FGW

Harborside Inc. (CSE: HBOR) (OTCQX: HBORF) has acquired 50.1% of FGW Haight Inc.'s equity, which holds read more

Cresco Labs CEO Discusses Cannabis Industry Challenges, Reaching Nationwide Customer Base

The main thing holding the cannabis industry back is access to capital, according to Cresco Labs Inc (OTCQX: CRLBF) CEO Charlie Bachtell. read more

Agrify CEO Urges Indoor, Climate-Controlled Cultivation To Mitigate Wildfire Damage

This Croptober, outdoor cannabis cultivators on the West Coast have been major victims of unexpected raging wildfires. read more